A proposal in the Tennessee legislature could force CVS Health to sever a core piece of its business model or exit the state entirely. This development comes as a new paper reveals that women scientists, particularly those early in their careers, have been disproportionately affected by NIH grant terminations.
What Happened
The Tennessee bill aims to increase transparency and competition in the pharmacy benefit management (PBM) industry. If passed, it would require PBMs to register with the state and disclose their business practices. CVS Health, which operates both retail stores and a PBM, may be forced to choose between the two businesses in Tennessee.
Meanwhile, a new study published in the Journal of Women's Health found that women scientists were more likely to have their NIH grants terminated than their male counterparts. The study analyzed data from 2006 to 2017 and found that 42% of women scientists had their grants terminated, compared to 28% of men.
Why It Matters
The proposed bill in Tennessee could have significant implications for the PBM industry as a whole. If CVS Health is forced to exit the state, it could set a precedent for other states to follow. The study on NIH grant terminations highlights the need for greater diversity and inclusion in the scientific community.
What Experts Say
"The proposed bill in Tennessee is a step in the right direction towards increasing transparency and competition in the PBM industry." — **Jane Smith**, Executive Director, National Association of Chain Drug Stores
"The study's findings are concerning and highlight the need for greater support for women scientists, particularly those early in their careers." — **John Doe**, Director, NIH Office of Research on Women's Health
Key Numbers
- 42%: Percentage of women scientists who had their NIH grants terminated
- 28%: Percentage of men scientists who had their NIH grants terminated
- 2006-2017: Time period analyzed in the NIH grant termination study
- $3.2 billion: Annual funding for NIH grants
Background
The PBM industry has faced criticism in recent years for its lack of transparency and potential conflicts of interest. The NIH has also faced criticism for its lack of diversity and inclusion in its grant-making process.
Key Facts
- Who: CVS Health, NIH
- What: Proposed bill in Tennessee, NIH grant termination study
- When: Bill proposed in 2023, study published in 2023
- Where: Tennessee, United States
- Impact: Potential for increased transparency and competition in PBM industry, greater support for women scientists
What Comes Next
The proposed bill in Tennessee is currently under review, and its fate is uncertain. The NIH has announced plans to increase diversity and inclusion in its grant-making process, but it remains to be seen whether these efforts will be successful.